Premium
5‐HT 3 Antagonists in the Treatment of Postoperative Nausea and Vomiting
Author(s) -
Pham Louise,
Langford Jane,
Williams Kylie
Publication year - 2003
Publication title -
journal of pharmacy practice and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.222
H-Index - 22
eISSN - 2055-2335
pISSN - 1445-937X
DOI - 10.1002/jppr2003334275
Subject(s) - medicine , antiemetic , postoperative nausea and vomiting , nausea , vomiting , placebo , anesthesia , intensive care medicine , alternative medicine , pathology
Background: Postoperative nausea and vomiting (PONV) can affect up to 30% of patients. While the use of antiemetics for prophylaxis has been extensively reported there is less evidence of their efficacy for the treatment of PONV. Aim: To review the evidence and discuss the use of 5‐hydroxytryptamine type 3 (5‐HT 3 ) antagonists for the treatment of PONV in Australia. Method: A literature search was conducted to identify clinical studies evaluating the effects of 5‐HT 3 antagonists in the treatment of PONV. Results: In four studies various doses of 5‐HT 3 antagonists were compared and in five studies a single dose of 5‐HT 3 antagonist was assessed against another antiemetic or placebo, or both. Conclusion: These studies indicate that 5‐HT 3 antagonists are effective and safe in the treatment of PONV.